Veeva Systems – A Deep Dive into a Misunderstood SaaS Stock, Now on Sale
A Deep Dive into Veeva Systems - a best-in-class SaaS stock at 16x FCF
There’s a particular kind of stock that makes for a frustrating watch from the sidelines: one where the business keeps doing exactly what it’s supposed to do, quarter after quarter, while the share price tells a completely different story. Veeva Systems is that stock right now. Down 44% over the past twelve months, swept up in a broad SaaS selloff built on fears that AI will gut the moats of incumbent enterprise software companies.
However, Veeva Systems doesn’t fit the AI disruption story it’s currently being priced for. Every dollar in pharma R&D and commercial operations runs through software that has to survive an FDA audit, and that single fact changes everything about how vulnerable a company actually is to a clever new agent or a horizontal competitor’s AI push. Veeva isn’t a generic CRM vendor or a horizontal productivity tool vulnerable to the next clever AI agent; it’s the compliance backbone for an entire global industry, embedded so deeply into the regulated workflows of pharmaceutical and biotech giants that ripping it out isn’t a software decision; it’s a multi-month regulatory ordeal.
Veeva isn’t some leveraged bet on a single product cycle or a story stock riding hype; it’s a profitable, founder-led company generating $1.6 billion in trailing free cash flow, sitting on $7.3 billion in cash with practically no debt, growing subscription revenue in the mid-teens with remarkable consistency since 2022. The business hasn’t blinked, while the stock has done little else.
Plenty of reason to take a real close look at this SaaS business. Therefore, today I will break down the business model, its moat, and growth prospects; address the AI threat; and review the financials and recent performance before covering the outlook and current valuation.
Is Veeva a good buy right now, and is it worth owning for the next 5-10 years? Let’s find out in this Veeva Systems Deep Dive!
Welcome to InvestInsights — an independent equity research publication rooted in long-term, buy-and-hold investing, publishing actionable stock/equity research reports weekly!
📈 You’re reading my latest [FREE] stock analysis. If you like this analysis, make sure to like & subscribe to receive much more like this, weekly!
This is Veeva Systems!
Business Fundamentals
Starting with the basics, Veeva Systems is a cloud software company focused exclusively on the life sciences industry (pharmaceutical, biotech, and medical device companies), an industry that has historically been underserved.
You see, the life sciences industry has extremely specific, heavily regulated workflows (compliance, FDA validation requirements, audit trails, electronic signatures, etc.) that generic enterprise software like Salesforce or SAP wasn’t built to handle out of the box. The industry also has unique processes with no equivalent elsewhere: managing physician call records and sample drops for sales reps, tracking clinical trial documents through regulatory submission, and coordinating safety/adverse event reporting.
Combine that with life sciences being a relatively small end market compared to verticals like retail, financial services, or general enterprise, and software giants have little incentive to build deep, purpose-made functionality for it. Therefore, life sciences was a post hoc customization bolted onto platforms designed for everyone else – pharma companies have historically spent years and tens of millions of dollars customizing generic CRM or content management platforms just to make them compliant.
Peter Gassner recognized this issue and founded Veeva in 2007, finding that building natively compliant, purpose-fit software for this one industry was a defensible niche big enough to matter (global pharma alone is worth hundreds of billions in revenue) but specialized enough that horizontal giants wouldn’t prioritize competing directly. And that is what has allowed Veeva to grow into a dominant force in its niche, with the vast majority of large pharmaceutical companies using at least one of its products.
Today, the company has a $26 billion market cap and generates just over $3 billion in annual revenue. By the way, Peter Gassner remains Veeva’s CEO today. Yes, this company is still founder-led, which is a huge plus. He also has serious skin in the game with a 7.5% stake.
Delving into the business in detail, what exactly does Veeva do? In practice, drug companies have to follow strict government rules for nearly everything they do, tracking sales visits to doctors, running clinical trials, getting drugs approved, and monitoring side effects. Veeva builds the specific software that handles each of those jobs from the ground up.
Its core product suite spans two main segments – Commercial Cloud (45% of revenue) and R&D Cloud (55% of revenue). Let’s start with Commercial Cloud, which is historically Veeva’s core business and the area where it is most dominant.
Commercial Cloud focuses on sales, marketing, and medical affairs. The flagship product of Commercial Cloud is Veeva CRM, used by pharmaceutical sales reps to manage physician relationships, sample distribution, and call planning, along with related tools for content management and multichannel marketing. This product alone brings in 20% of total revenue.
This is also where Veeva is most dominant, with an estimated 70-80% market share among large pharmaceutical and biotech companies, making it the de facto standard for salesforce automation in the industry. Most top-20 pharma companies use Veeva CRM in some capacity. This dominance is driven by its purpose-fit approach and two decades of compounding its early-mover advantage.
It’s worth noting that Veeva CRM was originally built on a platform licensed from Salesforce, with Salesforce receiving a per-seat royalty. Yet, over the last two years, Veeva has begun migrating customers off that licensed Salesforce infrastructure onto Vault CRM, its proprietary platform built on the same Vault architecture as its R&D products, thereby unifying the entire system.
Strategically, this matters for two main reasons: it eliminates the ongoing royalty payment to Salesforce (a margin benefit), and it removes Veeva’s dependence on a platform owned by a company that could become a competitor. A big move, and an important one in the long haul.
So far, the migration has progressed steadily. Over 150 customers are now live on Vault CRM (versus 115 in Q3 FY2026 and 125+ in Q4 FY2026), adding 27 in the last quarter alone and 40 customers migrating YTD. Additionally, 10 of 20 top biopharma decisions were won outright by Veeva versus 6 for Salesforce, and 4 are still undecided. Veeva has an 80% win rate in top-20 decisions this year, so clearly good traction. But more on this later.
Apart from CRM, Commercial Cloud also includes Veeva Vault PromoMats and MedComms, used to manage the creation, review, and approval of marketing and medical content, ensuring every piece of promotional material goes through proper legal/medical/regulatory review before reaching a doctor’s desk, with full audit trails – all designed to meet all regulations.
Veeva CRM Engage and OpenData round out the commercial suite. Engage covers virtual meetings and remote engagement tools (which saw a surge in importance post-COVID), while OpenData provides a master database of healthcare provider information that customers can license to keep contact and affiliation data up to date.
Then there is the R&D Cloud, the faster-growing segment that includes Veeva Vault, a suite of applications covering clinical trial management, regulatory submissions, quality management, and safety data, helping life sciences companies manage the entire drug development lifecycle in a single connected system.
Vault Clinical (CDMS, eTMF, CTMS) supports clinical trial operations, managing trial master files, tracking patient data, coordinating with investigator sites, and ensuring trial documentation is audit-ready for regulators. Vault RIM (Regulatory Information Management) helps companies track regulatory submissions and approvals across health authorities in different countries, which is critical because a drug might require separate dossiers for the FDA, EMA, and dozens of other regulators.
Here, Veeva has also built a dominant position, though competition here includes players like IQVIA, Oracle Health Sciences, and various point solutions, so the share is somewhat less concentrated than in CRM. Nonetheless, it is sufficiently dominant that IQVIA has previously filed an anticompetitive lawsuit against Veeva, primarily due to its bundling advantage. 35 of the top 50 pharma companies use Veeva Vault, and large customers are standardizing on it end-to-end, with Bristol Myers Squibb having more than 70% of its employees on the Veeva Vault Platform. Its main named challenger in clinical specifically is Dassault’s Medidata, though Veeva Vault EDC has been gaining ground on that historically dominant player.
R&D also includes Vault QualityDocs and QMS, which manage quality processes like deviations, CAPAs (corrective and preventive actions), and SOPs, helping manufacturing and quality teams stay audit-ready. Finally, Vault Safety is Veeva’s newer entrant into pharmacovigilance, handling adverse event case processing, a function previously dominated by older, clunkier legacy systems.
In quality management systems (Vault QMS) and safety (Vault Safety), Veeva is a newer but rapidly growing entrant, competing against incumbents like ArisGlobal in safety and various legacy QMS vendors. Share here is lower since these are more recently launched product lines, still taking share from incumbents, but Veeva has been seeing very strong traction, and above all, huge promise.
Crucially, all of these systems are built on the same underlying Vault platform, so customers adding a new application aren’t bolting on a separate system; they’re extending the same compliant, validated infrastructure.
R&D is Veeva’s main growth engine, having rapidly overtaken its core Commercial suite in recent years to become the largest by revenue. You can look at it like this: CRM is more mature and slower-growing, having become more of a cash cow than a growth engine, while R&D is the growth driver, with less mature products and loads of room for long-term growth, especially through cross-selling.
More importantly, across Veeva’s entire portfolio, the important takeaway is that its software isn’t optional for clients; it’s a compliance infrastructure. Pharma and biotech companies operate under FDA, EMA, and other global regulatory regimes that require audit trails, electronic signatures, and validated processes for nearly everything touching drug development, manufacturing, and commercialization. Veeva’s products aren’t productivity tools customers could live without; they’re the system of record that proves to regulators a company followed proper process.
Therefore, Veeva’s software sits at the intersection of being mission-critical to revenue (commercial functions) and mission-critical to legal/regulatory survival (R&D and quality functions), which is a rarer and stickier position than most “important” enterprise software occupies.
This is as non-cancellable to customers as you can find and very hard to replace, making Veeva’s revenue extremely reliable in an economic downturn. Growth could slow, of course, but existing modules won’t be cut to safe money – a pharma company can’t simply pause or swap out the system that runs its validated clinical trial documentation, regulatory submissions, or safety case processing, the way it might delay a marketing tool or a nice-to-have analytics platform during a budget crunch, since doing so risks compliance gaps that carry legal and patient-safety consequences far more costly than the software subscription itself.
Multi-year contracts reinforce this further, locking in revenue regardless of near-term sentiment. As a result, Veeva hasn’t reported a single quarter of negative growth since 2013. In fact, it has reportedly only a single quarter of growth under 10%, which is incredible stability.
With that, I think we have a good sense of what Veeva sells to its customers. The next step is how it generates revenue exactly.
The company operates on a subscription (SaaS) revenue model. A pharma company doesn’t buy Veeva’s software outright; it pays an ongoing subscription fee to use it, usually billed annually under multi-year contracts. The fee generally scales with the number of people at the company using the software (a “per-seat” model) and the number of different Veeva products they’ve signed up for.
There are really two buckets of things customers pay for. The bigger and more important bucket is subscription revenue (83% of total revenue), the recurring fee for actually using the software day-to-day, whether that’s the CRM tool the sales reps use or the Vault systems that manage clinical trials, regulatory filings, or quality documentation. This is the core, predictable, high-margin engine of the business.
The smaller bucket is services revenue (17% of total revenue), one-time fees for things like helping a customer set up the software, customize it for their specific processes, or migrate their data from an old system onto Veeva (this has become especially relevant lately with customers moving from the old Salesforce-based CRM to Veeva’s own Vault CRM). This isn’t recurring in the same way; it’s more like a consulting fee tied to a specific project.
Overall, it is quite simple and easy to understand.
What is worth noting before we move on is that Veeva’s revenue concentration is fairly high due to the nature of the industry. The top 20 pharma companies globally generate 50% of Veeva’s revenue, so losing any of these would be a serious drag. The pharma industry is quite concentrated in revenue terms, so this isn’t a surprise, but it is a risk worth considering.
On that, let’s assess its moat.
The Moat
Does Veeva have a moat? Yes, and quite a huge one, often named one of the strongest in SaaS.
There are a number of factors that give Veeva an impressive moat, but by far the most important is regulatory embeddedness. You see, in most industries, switching software is annoying but mostly a data-migration and retraining problem. In pharma, there’s an extra layer on top of that.
In pharma, regulators (FDA, EMA, etc.) require companies to prove, with documented evidence, that any software affecting drug development, manufacturing, or safety reliably performs its intended function every time. This proof process is called validation, and it includes writing test scripts, running them, documenting results, and keeping that paper trail on file.
So, once a pharma company validates Veeva CRM or a Vault application for GxP-compliant use, that validation process itself (documenting that the software works as intended for regulated purposes) is expensive and time-consuming to repeat, creating very high switching costs beyond typical software lock-in.
If a customer decides to rip out Veeva and switch to a competitor, they can’t just copy the old validation paperwork over to the new system. They have to redo the entire proof process for the new software, essentially proving from scratch that the new system is trustworthy for regulated work with regulators looking over their shoulders. And because Veeva is often connected to other regulated systems (say, your clinical trial software talks to your safety reporting software), swapping one piece can force you to re-check that the connections still work and are still compliant, too, like pulling one block out of a tower and needing to re-stabilize the blocks around it.
That’s what makes leaving Veeva so much more painful than leaving a typical SaaS vendor in industries without that compliance layer. And it scales with the degree to which Veeva becomes embedded – the more linked, validated processes a customer runs on Veeva, the more the domino effect of validation, ripping out any one piece, creates.
The result is a strong, defensible position for Veeva.
The second factor definitely worth considering is Veeva’s domain-specific product depth, built from years of working exclusively with this industry. The niche focus is precisely what generic horizontal vendors (Salesforce, SAP, Oracle) couldn’t or wouldn’t replicate, since the life sciences market wasn’t large enough on its own to justify the kind of deep, compliance-native product investment Veeva made, while being specialized enough that off-the-shelf tools never fit well.
That focus compounds over time in two ways. First, every dollar of R&D goes toward improving the product’s fit with pharma/biotech workflows, rather than being split across unrelated industries. Second, the company accumulates institutional knowledge of regulatory requirements, customer workflows, and industry relationships that a generalist competitor would need years to match, even if it decided to try.
In other words, thanks to Veeva’s niche focus on a highly complex, unique industry, competition is minimal, and its two decades of accumulated innovation, knowledge, and data are incredibly hard to match. And given the aforementioned high switching costs, Veeva customers need an undoubtedly better product to even consider switching.
In my view, these two factors give it an exceptional moat.
Network and ecosystem effects compound this. Veeva OpenData becomes more valuable as more companies contribute and use shared HCP data. Contract research organizations, consultants, and contractors are trained on Veeva systems, so using Veeva reduces friction when working with external partners who are already familiar with the platform.
Of course, this doesn’t mean it’s all plain sailing from here on out. Particularly, Veeva’s dominant position in CRM is facing pressure, partly because of its own move to migrate customers off the Salesforce platform onto its Vault-based CRM. This has created a rare moment of switching friction and opened a window for competitors like Salesforce itself (re-entering via partnerships) and Indegene or IQVIA’s offerings to pitch alternatives – the Vault CRM migration window is the moment where customers are forced to make an active choice rather than just renewing the status quo.
Positively, Veeva’s advantages are structural, not just incumbency. Salesforce’s core platform is horizontal; building deep, validated, GxP-compliant pharma-specific workflows (sample accountability, call reporting structures, MLR-linked content approval) from scratch is a multi-year undertaking, not a quick vertical bolt-on. Veeva has roughly two decades of accumulated domain-specific product depth that a generic platform can’t replicate by repackaging existing CRM features with a pharma label, not even in the AI age, due to a lack of data.
Confirming Veeva’s resilience even amid this period of weakness is the data. As mentioned earlier, 10 of the top 20 pharma companies globally have already committed to Vault CRM, with an 80% YTD win rate, proving the moat remains real. The fact that Veeva is winning the largest, most scrutinized accounts during the exact window where switching friction is lowest (forced migration) is the strongest evidence that the moat is holding
Ultimately, I do view Veeva’s competitive position as genuinely strong, probably among the stickiest enterprise software relationships outside of core ERP systems, thanks to the regulatory validation cost mechanism. I am not concerned about competitive disruption here.
Growth drivers
Absolutely one of the most important questions to ask ourselves: What can we expect from Veeva in terms of growth over the next 5-10 years?
And whereas the niche market focus greatly benefits Veeva’s competitiveness and moat, it does cap its TAM quite significantly relative to a horizontal player. Therefore, Veeva is much more dependent on growth within its existing customer base through cross-selling and entering new markets than acquiring new logos – with all of the world’s top 20 life sciences companies as customers, there’s no further “land” to do among the biggest pharma players, only “expand” by cross-selling additional Vault applications into accounts that may have started with just CRM or just one R&D module.
Today, 35 of the top 50 pharma companies globally use Veeva Vault across clinical, quality, regulatory, medical, and commercial processes, reflecting significant growth in product adoption in recent years. Most of these started with just CRM, but as Veeva rapidly expanded its product count over the last decade, its value to customers has grown significantly. And the runway remains large, so I expect this to remain its primary growth lever.
Positively, Veeva’s cross-sell position remains unusually strong, as it has an existing relationship with virtually every large pharma and biotech company on earth, a product suite that spans nearly every regulated workflow those companies run (commercial, clinical, regulatory, quality, safety), and a platform architecture (Vault) where each additional module shares the same validated infrastructure as the last, meaning the marginal cost and friction of adding another product for the customer is far lower than evaluating and onboarding an entirely new vendor.
That is a hugely strong position.
This has allowed R&D Cloud to overtake Commercial in revenue contribution in recent years, purely through cross-selling, with two decades of CRM dominance serving as the perfect “land” from which to expand by cross-selling its R&D Cloud products. For reference, CRM suite specifically now represents about 20% of total revenue, down from 25% two years prior, underscoring how much the growth algorithm has shifted toward diversification beyond the original CRM cash cow.
Meanwhile, Veeva reports it still has only penetrated 16% of its total TAM, suggesting there is plenty of room to grow with its existing product catalog through cross-selling.
Meanwhile, the company also continues to add products to its platform, further growing its TAM and addressable spend per customer. Take Vault Safety, which was launched quite recently. This is Veeva’s pharmacovigilance product, the system that pharma and biotech companies use to manage adverse event reporting. When a patient experiences a side effect from a drug anywhere in the world, that case must be captured, investigated, documented, and reported to the relevant regulators (FDA, EMA, and others) within strict timelines. Vault Safety is built to handle the entire case-processing workflow.
This is one of Veeva’s newer R&D Cloud product lines, and importantly, it’s not a category Veeva is creating from scratch; it’s displacing entrenched legacy incumbents, most notably Oracle Argus, which has dominated pharmacovigilance software for years. But Veeva is in a strong position to replace these legacy systems, exactly because it is already deeply entrenched in these giants and the Vault system is already validated – it is simply the best option.
There is also Veeva AI, the company’s umbrella initiative to embed AI agents directly into its existing applications. I will address AI in more detail later on, but the revenue potential is huge, directly expanding potential per-customer revenue through add-ons.
These kinds of platform expansions create significant growth potential.
Besides new products, Veeva also has room to move down-market into smaller biotechs and emerging companies, as well as adjacent verticals like medical devices and CDMOs.
Overall, while the room for new logos is very limited within its existing markets due to its already dominant position and presence in nearly every pharma giant, the company does have plenty of levels to fuel solid growth.
In terms of industry growth forecasts, the numbers look impressive, with the overall life science software market expected to grow at a 10-12% CAGR into the 2030s.
Broken down, the pharma QMS market is projected to grow at a 13% CAGR, and the RIM software market at an 11% CAGR through 2036, driven by large enterprise accounts ripping out fragmented legacy systems in favor of newer cloud-based systems, such as Veeva Vault. This drives significant value growth, even if the underlying numbers are less impressive. Furthermore, the clinical trials software market is forecasted to grow at a 12.5% CAGR through 2031, driven by increasing complexity and data demands of modern trial designs.
So far, so good. However, CRM is the clear laggard by comparison, with estimates pointing to a 4-6% CAGR through 2036. And especially with Veeva already dominating this market with a 70-80% market share, it is more likely to underperform here due to tougher competition than to outperform already low industry growth.
Clearly, growth will come from the R&D Cloud products, where I believe Veeva is well-positioned to outpace the market, given its strong cross-sell position and rapid innovation. Also, the migration is providing Veeva with a multi-year growth tailwind, as each successful migration is a renewal/repricing event and an opportunity to attach more Vault modules, so it’s simultaneously a defensive (moat-protecting) and offensive (expansion) motion. This high renewal activity can definitely add a few percentage points to growth, and this is expected to run through 2030.
Ultimately, given the migration, the room for cross-selling/low TAM penetration, and the solid industry growth forecasts, I definitely see room for Veeva to maintain a low-to-mid teens growth rate through 2030, say in the 12-15% range.
Beyond this, I expect the top-20 pharma cross-sell to be much more saturated, and the CRM migration tailwind will disappear, likely slowing down growth. Of course, AI is the wildcard here, and it could emerge as a considerable tailwind in the 2030s, though looking this far ahead remains uncertain. But considering the visible growth runway, I would expect growth to slow into the high single digits.
Nonetheless, I think this is an excellent outlook, especially for a business with a very strong moat. You get a reliable performer, hugely dominant in a niche, with little risk of disruption growing at a double-digit clip over the next 5 years.
That is an attractive backdrop, without a doubt.
AI – Disruption or Opportunity?
Then, onto the big question for any SaaS stock: Is AI a disruption risk or a long-term opportunity?
As I have argued before, I don’t believe the answer to this question is uniform for the entire industry, with certain players much more at risk than others – I don’t think the narrative is wrong, it just doesn’t hold up for the entire sector. I believe it is mostly user-habit moats (like Salesforce) and mid-sized functionality SaaS (like Monday or Atlassian) that are at risk.
Veeva falls in neither of these categories. Yet it has been beaten down along with the entire sector.
The main concern is that Veeva’s moat rests heavily on workflow embeddedness and the cost of validating software for regulated use, but AI could threaten this. For one, if general-purpose AI agents (think Salesforce’s Agentforce, or even a sufficiently capable horizontal LLM-powered tool) can ingest unstructured data and execute workflows that are compliant enough without needing a purpose-built system of record underneath, the “you must run this on Veeva’s validated infrastructure” argument weakens. Validation costs matter most when the software itself is the thing being validated; if AI increasingly sits on top of or beside the system of record rather than being deeply fused into it, switching the underlying system becomes comparatively less catastrophic.
Second, if AI agents become commoditized infrastructure, then Veeva’s specific advantage shifts from “we have better AI” to “we have better proprietary data and workflows to point AI at.” That’s a real moat, but it shifts the competitive battle from product depth (where Veeva has a 15+ year head start) to data depth and integration quality, a newer and less proven battleground for Veeva specifically.
These are fair concerns, though hugely blown out of proportion and a bit premature. Also, the risk is more real in CRM than in R&D/Quality/Safety. CRM workflows are closer to generic business processes that a strong horizontal AI agent could plausibly handle without deep domain-specific infrastructure, which is exactly where Salesforce’s Agentforce traction is showing up. Yet, the R&D side is more closely tied to regulatory validation and proprietary structured data, making it harder for a generic AI layer to simply bypass Veeva’s systems of record.
I don’t think the R&D side is really threatened, which is the primary drive of the business going forward.
Meanwhile, AI also provides a significant opportunity for Veeva. According to management, AI could boost efficiency in the life sciences industry by 15% by 2030 by addressing pain points in compliance-heavy workflows such as regulatory approvals, safety reporting, and clinical trials, meaning AI may expand the value of what Veeva already offers rather than replace it.
And Veeva’s architecture is perfectly suited to run AI Agents. Since the entire product stack runs on the Vault architecture, Veeva’s AI agents can work more seamlessly across the whole customer footprint. A unified architecture is simply easier to layer AI on top of than two structurally different platforms glued together.
Also, in life sciences specifically, general AI agents without access to Veeva’s deeply structured, compliant, proprietary data set are even less useful than in any other industry, simply because the value isn’t just intelligence; it’s intelligence fused with validated, auditable data lineage. That’s a harder thing for a horizontal AI vendor to replicate quickly.
Veeva’s AI Agents are built on LLMs from Anthropic and Amazon, hosted on Amazon Bedrock, designed for specific high-impact use cases like quality event summarization, investigation narrative generation, and document translation, with each agent understanding the application context and having direct, secure access to application data, documents, and workflows, avoiding the need for general-purpose AI that lacks domain specificity.
Veeva also recently announced Veeva Falcon, taking AI to the agentic level, not just helping humans do their job faster, but taking over certain repetitive jobs entirely. The two areas it’s starting with are sorting and classifying clinical trial documents, and triaging and categorizing safety cases. Both of these are high-volume, repetitive tasks that pharma companies today often pay outside specialist firms (think outsourced data-entry or document-processing vendors) to handle.
Veeva Falcon uses a usage-based payment model, unlike its core seat-based model. It plans to roll out Falcon in November. This is a strong move by Veeva to strengthen its position in the AI era.
I believe that, ultimately, life science giants are more likely to run AI through Veeva than replace it with third-party LLMs, making AI more of an opportunity than a threat. Running AI through the already-embedded system genuinely is the lower-friction, lower-risk path, and that matters an awful lot in this industry. The economics to go any other way don’t make sense.
Nonetheless, I agree that CRM remains more exposed, in part due to Salesforce’s push with Agentforce, and it being a more generic business process. Yet overall, the fear of AI disruption seems well overblown.
With that tackled, let’s assess Veeva’s financials and performance!
Financials & Performance
Veeva released its latest financial results – fiscal Q1 2027 – on June 3, delivering impressive numbers across the board and once more highlighting that it is not seeing any loss of momentum due to AI. Growth remained stable and impressive; margins are best-in-class and expanding; cash flows are excellent; and financial health is brilliant. Management even raised its fiscal FY27 guidance due to better-than-expected deal momentum.
Breaking down the numbers, Veeva reported total fiscal Q1 revenue of $883 million, beating the consensus by $25 million and up 16% YoY. This is pretty much in line with the prior four quarters, with Veeva consistently delivering very strong mid-teens growth, showing no loss of momentum at all – Q1 was no different.
Sure, growth has slowed from the high-growth phase in the 2010s, slowing into the mid-teens post-COVID, but what matters to me is that it has remained nearly perfectly stable here since 2022, with growth consistently in the low-to-mid-teens, actually accelerating from 2024 into 2025 and now into 2026. That is impressive.
Driving the strong growth today and the step-up from 2024 is likely the crossover between R&D and Commercial, with the faster-growing segment now the largest, providing the overall growth rate with a fresh internal engine. Also, the Vault CRM migration serves as a built-in renewal and re-engagement cycle, prompting active conversations with the entire commercial customer base rather than passive auto-renewals, thereby driving additional growth.
Especially with this migration lasting through at least 2029 (by when all customers should be migrated), expected to accelerate in 2027 and 2028, and Veeva’s R&D Cloud products still far from mature and with a long runway, this momentum does seem sustainable, especially if ramping AI revenues are layered on top.
Regarding the CRM migration, momentum looks good, as mentioned earlier. It added 27 new Vault CRM customers in Q1, bringing the total to over 150, and momentum is accelerating, aided by an 80%-win rate. Within the top 20, Veeva now has 10 wins, with 6 for Salesforce and 4 still up for grabs, of which Veeva expects to win the majority, suggesting it expects 13-14 of the top 20 pharma giants globally to run on Vault CRM.
Ultimately, this drove 15% growth in subscription revenue to $730 million, with strong contributions from both R&D and Commercial. In R&D, Veeva saw particular strength in its quality Cloud, with 18 new deals for QualityDocs, 23 for QMS, and 20 for Training, driving R&D Cloud revenue up 19% YoY. Commercial Cloud revenue was up 11% YoY, which is a balance about as expected. Also, Services revenue grew strongly, up 23% YoY to $153 million, driven by higher consulting revenue from the CRM migration.
Overall, top-line momentum looks strong, coming in ahead of expectations.
Moving to the bottom line, there are some areas of attention, but overall momentum looks good. The Q1 gross margin hit 76.9%, down 230 bps YoY. This decline was driven by faster growth in lower-margin services revenue and a 130 bps lower subscription gross margin, likely due to higher computing costs related to the Vault CRM migration. The migration is posing a near-term headwind, as computing costs are scaling faster than Salesforce royalties are being canceled during the transition period, which is reflected in the gross margin. I expect this to be largely temporary, allowing for margin upside in the coming years.
Further down the line, Veeva demonstrated excellent cost control, with operating expenses up just 13% YoY, growing more slowly than revenue, driving operating leverage. On the cost front, R&D and S&M costs were up 15% YoY, offset by just 2% growth in G&A.
This, in part, offset the gross margin pressure, but not entirely, resulting in operating income growth of 13% YoY to $395 million, reflecting an operating margin of 44.8%, down 130 bps YoY, mainly due to the gross margin decline, though still ahead of guidance.
Also, looking at the graph below, Veeva has delivered excellent margin expansion through operating leverage in recent years. The gross margin headwind is now a drag, but I see plenty of room for the operating margin to keep expanding in the coming years.
Ultimately, Veeva reported a fiscal Q1 EPS of $2.24, beating the consensus by $0.10.
It is worth pointing out that Veeva does still spend a fair share on SBC, which means the GAAP operating margin is a bit lower, in the low 30s, which is still solid. Positively, SBC has been declining sharply as a percentage of revenue in recent years, dropping nearly 4 percentage points over three years.
As of Q1, SBC was 13.5% of revenue, a new all-time low and down 60 bps YoY. Yes, this is still somewhat elevated, but for a SaaS stock growing in the mid-teens steadily and with this declining consistently, I deem it acceptable and not much of a concern.
To round up the financials, Veeva reported a Q1 FCF of $1.13 billion, quite elevated due to the timing of realizations. On a TTM basis, this totals $1.64 billion at a very strong 49% FCF margin. Veeva consistently reports excellent cash flows, with its margin in the high-thirties to low-40s in recent years, hitting 43% in fiscal FY26.
This allowed management to repurchase $221 million in shares and significantly strengthen the balance sheet. Veeva ended Q1 with $7.3 billion in cash and practically no debt, leaving it with a fortress balance sheet.
As a cherry on top, Veeva’s reinvestment metrics are also solid, though somewhat unimpressive. Its LTM ROE is 14%, and its LTM ROIC is 13%, both roughly in line with recent years. These are solid numbers, above WACC, indicating management knows how to generate shareholder value.
More content like this? Consider InvestInsights Premium
InvestInsights Premium is designed to help you find best-in-class compounders, identify deep-value opportunities, avoid costly mistakes, and stay focused on fundamentals when markets get noisy, with full transparency into how I make decisions over time.
In practice, this gets you:
6–8 Research Reports per month, 2x more than free subs do, which includes 3-4 Deep Dives like this one!
Full visibility into my personal portfolio, including allocations, transactions, and conviction levels
An overview of target prices and ratings, updated weekly
Price tag? Only $95 per year or $9.50 a month. That comes to just $1 per analysis, with the rest provided at no cost.
Sound useful? You can upgrade to Premium today using the button below!
Outlook & Valuation
As always, let’s start with management’s guidance, which was raised following strong Q1 results, healthy deal momentum, and a CRM migration progressing well. Management now guides to fiscal FY27 revenue between $3,635 and $3,645 million, a $45 million increase from prior guidance, reflecting 14% YoY growth and comfortably clearing the $3.6 billion consensus.
This assumes subscription revenue of $3.06 billion, up 14% YoY, with Commercial Cloud revenue of $1.4 billion (up $15 million from prior guidance), reflecting the Q1 outperformance. R&D Cloud revenue is expected to be $1.67 billion, up $5 million from prior guidance, and service revenue is expected to be $580 million, up $25 million from prior guidance amid strong demand related to the CRM migration.
Moving to the bottom line, management now guides to an FY27 operating income of $1.61 billion, reflecting a 44% operating margin, up $20 million from prior guidance, driven by better-than-expected revenue but also a slightly lower margin due to higher computing costs. Ultimately, this translates to a FY27 EPS of $9.05, well ahead of a $8.85 pre-earnings consensus.
Looking further ahead, management remains committed to its 2030 targets, aiming for a $6 billion revenue run rate, with $4 billion coming from R&D Cloud and $2 billion from Commercial Cloud. This should come with a minimal operating margin of 35%.
Let me then move to my own forecasts. As discussed, the backdrop for Veeva looks very good. Given the migration, the room for cross-selling/low TAM penetration, and the solid industry growth forecasts, I definitely see room for Veeva to maintain a low-to-mid teens growth rate through 2030, say in the 12-15% range, and that might be conservative, as tailwinds are strong, especially if Veeva’s AI products find traction.
Starting with FY27, I expect Veeva to exceed its current outlook and deliver 14.5% revenue growth, driven by solid subscription revenue and better-than-expected services revenue. On the bottom line, I expect margin pressure to persist throughout the year, resulting in slightly slower EPS growth of 12%, just above management’s guidance, thanks to some revenue upside.
Looking further ahead, I expect growth to moderate to the 13-14% range through fiscal FY30, being conservative in any assumptions about AI, given that this product remains in its very early stages and the revenue ramp and adoption are uncertain, but this does offer a good bit of upside potential to these assumptions. On the bottom line, I am cautious. I expect the migration ramp in 2028 and 2029 to put continued pressure on margins amid higher computing costs and a gradual cancellation of Salesforce royalties. Therefore, I expect EPS to grow more slowly than revenue in 2028 and 2029, before Veeva’s margins begin to recover in fiscal 2030, allowing for an EPS growth acceleration.
These assumptions are reflected in the financial model below!
That brings me to valuation, and with Veeva shares down 44% over the past twelve months and 30% YTD amid the broader sell-off of the SaaS sector, despite Veeva’s business firing on all cylinders, Veeva is trading at record low multiples – multiples that are honestly totally ridiculous. At a current price of $153, shares trade at:
17x 2026 earnings
A PEG of 1.3x
16x 2026 FCF (consensus)
For a business of this quality and with this kind of outlook – highly reliable, subscription-based revenues, strong moat, dominant in its niche, growing mid-teens, a fortress balance sheet, healthy reinvestment metrics, and poised to keep growing at mid-teens through 2030 – 17x earnings and 16x FCF are ridiculous multiples.
This is as ridiculous as valuations get for a business of this caliber, and the market reaction looks far more like a sentiment purge than a fundamentals-driven repricing. Historically, Veeva has traded at a significant premium to the broader software sector, given its moat, durable growth, and best-in-class margins, with multiples regularly in the 30-40x earnings range during periods of comparable or even slower growth. The current 17x earnings and 16x FCF effectively price in either a sustained, multi-year growth deceleration into the high single digits, or genuine doubt about the durability of the moat itself, neither of which the actual data we’ve walked through here supports.
If anything, the quarter just delivered (accelerating subscription growth, a CRM migration win rate above 80%, raised guidance, and a gross margin headwind that looks temporary and migration-related rather than structural) argues for a re-rating higher, not a multiple this depressed. A PEG of 1.3x for a company growing mid-teens with expanding TAM penetration, a multi-year cross-sell runway, and an AI option that hasn’t even begun contributing meaningfully to revenue is, on its face, a disconnect between price and business quality that’s hard to justify on fundamentals alone.
Even under highly conservative assumptions, Veeva seems undervalued at $153. Say we apply a 20x multiple to current fiscal 2029 profits, which reflects minimal multiple expansion from current levels, while I will argue it deserves to revalue much higher once sentiment improves and the AI disruption narrative gets proven wrong – this is me being very conservative, as a business of this quality growing mid-teens can easily trade at 25-30x – I calculate an end-of-fiscal 2029 target price of $230.
From a current share price of $153, this implies potential annualized returns of 16%, which is about 2x the average return from the S&P 500 over the last two decades and above my 15% threshold, and that is on very conservative assumptions.
In other words, amid a sentiment-driven price slump over the past year, the risk-reward here for Veeva looks extremely attractive. Under more optimistic assumptions, Veeva shares can deliver stunning 25-30% annualized returns from here, and that requires no heroics, just steady compounding.
In conclusion, I believe Veeva is one of the most misunderstood, undervalued stocks out there right now. I deem current levels highly attractive!
Rating + fair value: Buy - Accumulate below $165
2028 Target Price: $230
Implied CAGR from current price: ~16%
Please leave a like if you enjoyed this post and found it valuable!
I'm just waiting for the moment when the market realizes how great Veeva is! It's a true compounding machine and the management announced some potentially huge growth drivers like falcon which should've fueled the stock with some energy- but yet it's still down. So I'm just patiently waiting for the reversal 😅
Thank you for your good work. One issue I have with the calculation of FCF is that it excludes SBC and related tax. I don't see how this can be completely excluded as it is a real cost for the company.